Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAR1 pathway polymorphisms and ticagrelor response study
ChiCTR-OPN-15006160Phase 4Recruiting
- Sponsor
- Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Pharmacogenetics Research Institute, Xiangya Hospital, Central South University. Primary endpoints: cardiovascular death, nonfatal myocardial infarction and 7 more. Started Apr 2014; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR-OPN-15006160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-15006160.